TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15261317
Drug: nitroglycerin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitroglycerin + ephedrine 0.1 mg/kg i.v.
Study: 15261317
Drug: nitroglycerin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitroglycerin + ephedrine 0.15 mg/kg i.v.
Study: 15261317
Drug: trimethaphan +
Normalized name: trimethaphan
DrugBank: Trimethaphan (DB01116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethaphan + ephedrine 0.1 mg/kg i.v.
Study: 15261317
Drug: trimethaphan +
Normalized name: trimethaphan
DrugBank: Trimethaphan (DB01116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethaphan + ephedrine 0.15 mg/kg i.v.
Study: 1583417
Drug: Methylphenidate (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (optimal dose for 6 weeks)
Study: 1583417
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 week without medication)
Study: 1583417
Drug: Methylphenidate (return
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (return to medication after placebo)
Study: 3159547
Drug: Depo-medroxyprogesterone acetate
Normalized name: medroxyprogesterone Injection [Depo-Provera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-medroxyprogesterone acetate (DMPA) 50 mg/month
Study: 3159547
Drug: Depo-medroxyprogesterone acetate
Normalized name: medroxyprogesterone Injection [Depo-Provera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-medroxyprogesterone acetate (DMPA) 100 mg/month
Study: 3159547
Drug: Depo-medroxyprogesterone acetate
Normalized name: medroxyprogesterone Injection [Depo-Provera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-medroxyprogesterone acetate (DMPA) 200 mg/month
Study: 3159547
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate (TC) 250 mg/month
Study: 3159547
Drug: Post-discontinuation of
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discontinuation of DMPA
Study: 3159547
Drug: DMPA administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMPA administration
Study: 29043412
Drug: Etirinotecan pegol
Normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etirinotecan pegol (EP) 145 mg/m2 Q21d
Study: 29043412
Drug: Irinotecan 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 350 mg/m2 Q21d
Study: 25391324
Drug: Bridge exercises
Normalized name: benzalkonium chloride Topical Cream [Abridge Cold Sore]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridge exercises with a sling and micro vibrations (therapy group)
Study: 21563962
Drug: 1250 mg
Normalized name: bran 1250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg of Neuravena®
Study: 21563962
Drug: 2500 mg
Normalized name: inulin 2500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2500 mg of Neuravena®
Study: 18486257
Drug: Increased basal/total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased basal/total daily insulin ratio (B/TD ratio) from about 0.35 to about 0.46+/‐0.12 without change of total insulin daily dose
Study: 12937241
Drug: Pre-emptive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive oral ganciclovir therapy
Study: 12937241
Drug: Conventional deferred
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional deferred treatment (control group)
Study: 9250252
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide 20 mg
Study: 3735283
Drug: Subacromial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial injection of 40 mg of triamcinalone acetonide
Study: 3735283
Drug: Oral indomethacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral indomethacin, 100 mg/day
Study: 23529570
Drug: Dapagliflozin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (up to 10 mg/day)
Study: 23529570
Drug: Glipizide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (up to 20 mg/day)
Study: 10965198
Drug: Preoperative CA125
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative CA125 levels <35 IU/ml
Study: 10965198
Drug: Preoperative CA125
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative CA125 levels >=35 IU/ml
Study: 744492
Drug: Pomeroy's Kroener's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomeroy's Kroener's or a combination of both surgical procedures
Study: 24284086
Drug: Oral 5-aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-aminolevulinic acid (5-ALA)
Study: 21176727
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of roflumilast (ROF) 500 µg
Study: 21176727
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of roflumilast (ROF) 150 µg
Study: 18637718
Drug: 10% citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% citric acid solution
Study: 18637718
Drug: 5.25% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.25% sodium hypochlorite (NaOCl) solution
Study: 9295593
Drug: Neoral (converted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (converted from Sandimmune on a 1:1 dosing basis)
Study: 30167655
Drug: Modified Mindfulness-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Mindfulness-Based Stress Reduction (MBSR) training, weekly 2-hour classes and 20 minutes of daily home practice over 8 weeks.
Study: 22147287
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg three times a day for 10 days)
Study: 22147287
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg three times a day for 10 days)
Study: 22147287
Drug: Metoclopramide (follow-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (follow-on prescription)
Study: 20653798
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination therapy (polypill) with aspirin 81 mg, enalapril 2.5 mg, atorvastatin 20 mg, and hydrochlorothiazide 12.5 mg
Study: 18411606
Drug: Local adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local adrenaline administration into the surgical field before wound closure
Study: 8605133
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogen vaginal cream
Study: 1524045
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 240 mg/day orally for at least 2 months
Study: 6388425
Drug: Naftidrofuryl (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (600 mg daily)
Study: 29052225
Drug: Peripheral nerve
Normalized name: Peripheral nerve antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral nerve blocks with pre‐emptive ibuprofen and paracetamol
Study: 20179751
Drug: Standard 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 6 month anti-tuberculosis (TB) therapy
Study: 11790638
Drug: Transdermal xanomeline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal xanomeline, an M1‐selective cholinergic agonist, administered for 4 months.
Study: 11790638
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered for 4 months.
Study: 10618939
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol 1.3 g
Study: 17416906
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg
Study: 10618939
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol and diclofenac
Study: 8543846
Drug: hMG preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG preparation containing a 3:1 ratio of FSH/LH (Group A)
Study: 1935730
Drug: Oxamniquine 750
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxamniquine 750 mg
Study: 1935730
Drug: Oxamniquine 1000
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxamniquine 1000 mg
Study: 1935730
Drug: Oxamniquine 1250
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxamniquine 1250 mg
Study: 6775094
Drug: medroxyprogesterone acetate,
Normalized name: medroxyprogesterone acetate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: medroxyprogesterone acetate, 20 mg
Study: 30422368
Drug: Esomeprazole 10
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 10 mg once daily
Study: 30422368
Drug: Esomeprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (10 mg or 20 mg)
Study: 17507833
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (CEE) 0.625 mg/d
Study: 17507833
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (TD E2) 0.05 mg/d
Study: 28938478
Drug: Glucose-insulin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin infusion
Study: 20419730
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment at a mental health clinic
Study: 18701831
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment (20‐40 mg/day)
Study: 18701831
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (STPP and fluoxetine)
Study: 17085376
Drug: HRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT with 1 mg/day micronized 17beta-estradiol and 10 mg/day dydrogesterone for 14 days of each 28-day cycle
Study: 1325762
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated estrogen with 2.5 mg of micronized medroxyprogesterone acetate daily continuously (group C-2.5)
Study: 1325762
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated estrogen and 5.0 mg of micronized medroxyprogesterone acetate daily continuously (group C-5)
Study: 1325762
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated estrogen on days 1 through 25 and 5 mg of micronized medroxyprogesterone acetate on days 14 through 25 (group S-5)
Study: 6363096
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg once daily metoprolol Durules
Study: 6363096
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg metoprolol and 25 mg hydrochlorothiazide (Selokomb)
Study: 6363096
Drug: Change from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change from double dose of metoprolol Durules to combination therapy
Study: 30885955
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg daily for 8 weeks
Study: 30025009
Drug: Subcrestal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcrestal implants (1 mm subcrestally placed)
Study: 30025009
Drug: Crestal implants
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crestal implants (placed at the bone crest level)
Study: 26655606
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant 0.7 mg
Study: 21519291
Drug: ACU-4429 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACU-4429 (2 mg to 75 mg)
Study: 17439908
Drug: Interferon‐beta1a (IFN‐beta1a),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐beta1a (IFN‐beta1a), 22 mug subcutaneously weekly
Study: 11904789
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard pharmacological antiemetic treatment: metoclopramide and dexamethasone i.v.)
Study: 29524454
Drug: Vamorolone (0.1-20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vamorolone (0.1-20.0 mg/kg single doses; 1.0-20 mg/kg/day for 14 days)
Study: 25786050
Drug: Multicomponent exercise
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent exercise programme (24 twice-weekly sessions of combined aerobic, muscle strength training exercises and education)
Study: 23924790
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg + GVAX
Study: 19149323
Drug: Cognitive-rehabilitation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-rehabilitation and problem-solving therapy intervention
Study: 1245792
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDC), 750 mg per day
Study: 1245792
Drug: Phenobarbital (PB),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (PB), 90 or 180 mg
Study: 1245792
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CDC and PB
Study: 30796143
Drug: 12-week regimen
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week regimen of doxycycline or clarithromycin/hydroxychloroquine after a 2-week open-label regimen of intravenous ceftriaxone
Study: 30796143
Drug: 2-week regimen
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week regimen of intravenous ceftriaxone
Study: 28698186
Drug: Fasting serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting serum insulin levels
Study: 28698186
Drug: Fourth quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth quartile of insulin
Study: 28698186
Drug: Insulin:glucose molar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin:glucose molar ratio
Study: 23404232
Drug: Standard regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard regadenoson injection at rest
Study: 2953501
Drug: Sufentanil bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil bolus 0.1 microgram X kg‐1 followed by continuous sufentanil infusion of 0‐7 micrograms X min‐1
Study: 2953501
Drug: Fentanyl bolus
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl bolus 0.7 microgram X kg‐1 followed by continuous fentanyl infusion of 0‐50 micrograms X min‐1
Study: 29655134
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care (UC) including pharmacotherapy and counseling sessions
Study: 15142001
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of creatine (20 g per day for 6 days) and sodium bicarbonate (0.3 g per kg body weight 2 hours before swims)
Study: 15142001
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of creatine and sodium bicarbonate
Study: 11676942
Drug: Adjunctive PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive PCI (TIMI 2 or 3 flow at 90 minutes)
Study: 9570429
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) tablet
Study: 9570429
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) spray
Study: 9570429
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) spray
Study: 2438638
Drug: IM or
Normalized name: Betim Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM or oral iron treatments
Study: 25176223
Drug: Myocet (M)
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocet (M) 60 mg/m2 i.v. plus cyclophosphamide (C) 600 mg/m2 on Day 1 of a 21‐day cycle (Arm A)
Study: 25176223
Drug: Myocet (M)
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocet (M) 50 mg/m2 plus vinorelbine (V) 25 mg/m2 i.v. on Day 1 and V 60 mg/m2 orally on Day 8 on a 21‐day cycle (Arm B)
Study: 17426001
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous analgesia
Study: 16279895
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with 2 mg/kg body weight of Photosan-3, light activation performed 48 hours after intravenous application
Study: 9208360
Drug: Generic verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic verapamil (120 mg twice daily for 14 days)
Study: 9208360
Drug: Brand-name verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand-name verapamil (120 mg twice daily for 14 days)
Study: 31990936
Drug: Anagliptin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagliptin (200 mg twice daily)
Study: 31990936
Drug: Control (previous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (previous treatment schedules)
Study: 27096722
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250‐μg metered‐dose inhaler
Study: 27096722
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo metered‐dose inhaler
Study: 24196464
Drug: One-to-one therapy
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-to-one therapy
Study: 24196464
Drug: Group-based therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based therapy
Study: 19506003
Drug: Cardiac rehabilitation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac rehabilitation with controlled breathing (6 breaths/min for 10 minutes twice daily during the eight-week treatment period)
Study: 15277159
Drug: High zinc
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High zinc intake (12 mg/d)
Study: 15277159
Drug: Low zinc
Normalized name: insulin low zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low zinc intake (4 mg/d)
Study: 10930963
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 1600 microg twice daily
Study: 10930963
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 1000 microg twice daily
Study: 9024229
Drug: recombinant DNA‐derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant DNA‐derived preparations of human GH
Study: 30782712
Drug: Acupuncture intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acupuncture intervention (one treatment for five consecutive weeks)
Study: 30782712
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment offered after 6 weeks)
Study: 25216762
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and capecitabine (L-CAP)
Study: 19921305
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT), 10 sessions
Study: 18844819
Drug: Sleep therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep therapy (multi-component intervention including sleep restriction, cognitive behavioral therapy, bright-light therapy, structured physical activity, and body temperature manipulations)
Study: 12874586
Drug: Gelatine-coated Dacron
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatine-coated Dacron (GEL-D) grafts
Study: 10583440
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (30 ppm, 30 min)
Study: 10583440
Drug: Aspirin (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (640 mg x 1 orally)
Study: 8913542
Drug: Losartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 200 mg
Study: 8913542
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg (multiple dosing)
Study: 8913542
Drug: Placebo (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (multiple dosing)
Study: 7965263
Drug: Losartan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (all doses)
Study: 16837887
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (CEE)
Study: 6613808
Drug: Verapamil, 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 320 mg per day
Study: 26866518
Drug: Secukinumab (300,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (300, 150 mg)
Study: 25529851
Drug: Intramuscular dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular dexmedetomidine (1 µg·kg‐1)
Study: 25529851
Drug: Midazolam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.02 mg·kg‐1)
Study: 15084616
Drug: Gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine + Tipifarnib (200 mg bid orally continuously; gemcitabine at 1,000 mg/m² intravenously weekly x 7 for 8 weeks, then weekly x 3 every 4 weeks)
Study: 15084616
Drug: Gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine + Placebo (gemcitabine at 1,000 mg/m² intravenously weekly x 7 for 8 weeks, then weekly x 3 every 4 weeks)